DNER and cancer: BET proteins, specifically BRD4, have demonstrated potential as drug targets in lung and other cancers leading to the initiation of a myriad of clinical trials3,7,25; however, mechanisms of response and resistance to these inhibitors are still poorly understood, especially across different cancer types.